(+)-Catechin Clinical Trials

Size	Price	Qty
5mg	USD 147

Clinical Trials

Numerous clinical trials evaluate (+)-catechin and related green tea polyphenol formulations across diverse therapeutic areas, spanning Early Phase 1 through Phase 4 studies. These investigations address conditions such as bladder cancer, multiple myeloma, hepatic cirrhosis, influenza infection, and pulmonary arterial hypertension. Conducted by government agencies, major universities, and specialized research institutes, the trials encompass completed, active, terminated, and withdrawn recruitment statuses.

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06015022	RECRUITING	Cirrhosis, Liver	University of Texas Southwestern Medical Center	2024-09-01	PHASE2
NCT07161726	RECRUITING	Mobility Disability	University of Alabama at Birmingham	2026-04-21	PHASE1; PHASE2
NCT04300855	ACTIVE_NOT_RECRUITING	Prostate Cancer; Prostate Adenocarcinoma	H. Lee Moffitt Cancer Center and Research Institute	2020-08-21	PHASE2
NCT04597359	ACTIVE_NOT_RECRUITING	Prostate Carcinoma	ECOG-ACRIN Cancer Research Group	2021-10-05	PHASE2
NCT07149506	ENROLLING_BY_INVITATION	Radiation Dermatitis Acute; Radiation Dermatitis; Fibrosis; Skin	CARLOS FRANCISCO SAAVEDRA GARCIA	2025-09-01	PHASE3
NCT06631820	RECRUITING	Chronic Kidney Disease(CKD); Myosteatosis; Mitochondrial Dysfunction; Muscle Function; Muscle Mass	Karolinska Institutet	2025-01-17
NCT05811403	COMPLETED	Irreversible Pulpitis	Cairo University	2023-07-01
NCT06107192	COMPLETED	Healthy; Controlled Feeding Trial	University of Maryland, College Park	2023-12-07
NCT06604390	COMPLETED	Elderly Individuals Aged 60 Years or Older; Mild Cognitive Impairment (MCI)	Rahmi Novita Yusuf	2024-02-01
NCT05988788	COMPLETED	Necrotic Pulp	Cairo University	2023-10-01
NCT03278925	UNKNOWN	Cirrhosis	National Cancer Institute (NCI)	2018-08-09	PHASE1
NCT05113498	COMPLETED	Diet Modification	University Ghent	2021-11-01
NCT04386304	COMPLETED	Becker Muscular Dystrophy	Epirium Bio Inc.	2020-07-13	PHASE1
NCT02490527	COMPLETED	Statin Intolerance	University of California, San Diego	2015-06
NCT03826017	COMPLETED	Cognitive Function	Chonbuk National University Hospital	2018-12-05
NCT03213340	COMPLETED	Biological Aging	Abbott Nutrition	2017-09-14
NCT02660112	COMPLETED	Friedreich's Ataxia	Ralitza Gavrilova	2016-09	PHASE2
NCT01856868	COMPLETED	Becker Muscular Dystrophy	Craig McDonald, MD	2013-05	PHASE1; PHASE2
NCT03382067	COMPLETED	Test Anxiety	Prof. Dominique de Quervain, MD	2017-12-04
NCT03214133	COMPLETED	Collagen Synthesis	University of California, Davis	2017-05-23
NCT02964377	COMPLETED	Duchenne Muscular Dystrophy	Craig McDonald, MD	2016-11	PHASE1; PHASE2
NCT03236662	COMPLETED	Becker Muscular Dystrophy	Craig McDonald, MD	2016-11	PHASE2
NCT02015312	COMPLETED	Light Chain (AL) Amyloidosis; Cardiac Involvement	Florian Michel	2013-04	PHASE2
NCT03194620	COMPLETED	Healthy	University of California, Davis	2016-08
NCT02898571	UNKNOWN	The Impact of Vitamin c and Epicatechin Upon Antioxidant Capactity	Newcastle University	2016-07
NCT02013856	COMPLETED	Blood Pressure	Quadram Institute Bioscience	2014-07
NCT02656212	COMPLETED	Pre-diabetes	Veterans Medical Research Foundation	2015-09	PHASE1
NCT00799890	COMPLETED	Multiple Sclerosis	Friedemann Paul	2009-05	PHASE2; PHASE3
NCT02292342	COMPLETED	Vasodilation	University of Reading	2014-05	EARLY_PHASE1
NCT02731495	COMPLETED	Traumatic Brain Injury	National Nutrition and Food Technology Institute	2015-03	PHASE2; PHASE3
NCT02330276	COMPLETED	Pre-diabetes	Veterans Medical Research Foundation	2014-09	PHASE1
NCT01606124	TERMINATED	Advanced Colorectal Adenomas; Adenocarcinoma of the Colon; Stage I Colon Cancer; Stage II Colon Cancer; Stage III Colon Cancer	Mayo Clinic	2012-06	PHASE2
NCT02408289	COMPLETED	Obesity	Brooklyn College of the City University of New York	2015-03
NCT02068040	COMPLETED	Heart Failure	University of California, San Diego	2014-01
NCT01671514	COMPLETED	Heart Failure; Type 2 Diabetes	University of California, San Diego	2012-07
NCT02221791	COMPLETED	Endothelial Dysfunction; Bioavailability	Wageningen University	2014-06
NCT01880866	WITHDRAWN	Pulmonary Arterial Hypertension	University of California, San Francisco	2013-07	PHASE1
NCT01585519	COMPLETED	Cardiovascular Disease	Queen's University, Belfast	2012-04
NCT00253643	COMPLETED	Precancerous Condition; Prostate Cancer	OHSU Knight Cancer Institute	2005-07
NCT00377507	TERMINATED	Elderly	Masahiro Morikawa	2006-10
NCT01690676	COMPLETED	Borderline Hypertension	Danisco	2012-08	PHASE2
NCT01018615	COMPLETED	Chronic Hepatitis C; Oxidative Stress	University of North Carolina, Chapel Hill	2009-11	PHASE1
NCT01691404	COMPLETED	Hypertension; Endothelial Dysfunction	Wageningen University	2012-09
NCT00666562	COMPLETED	Stage I Bladder Cancer; Stage II Bladder Cancer; Stage III Bladder Cancer	National Cancer Institute (NCI)	2008-07-02	PHASE2
NCT00942422	TERMINATED	Multiple Myeloma and Plasma Cell Neoplasm; Precancerous Condition	Barbara Ann Karmanos Cancer Institute	2009-11	PHASE2
NCT01490008	COMPLETED	Anogenital Warts	MediGene	2011-12	PHASE1
NCT00611650	TERMINATED	Lung Cancer; Precancerous Condition; Tobacco Use Disorder	British Columbia Cancer Agency	2006-10	PHASE2
NCT01097226	COMPLETED	Healthy	Quadram Institute Bioscience	2010-04
NCT00303823	COMPLETED	Cervical Cancer; Cervical Intraepithelial Neoplasia Grade 1; Human Papilloma Virus Infection	National Cancer Institute (NCI)	2005-09	PHASE2
NCT00233935	COMPLETED	Barrett Esophagus	National Cancer Institute (NCI)	2005-11	PHASE1
NCT01082302	COMPLETED	Genital Warts; Perianal Warts	MediGene	2010-01	PHASE4
NCT00459407	COMPLETED	Adenocarcinoma of the Prostate; Stage I Prostate Cancer; Stage II Prostate Cancer	National Cancer Institute (NCI)	2007-03	PHASE1
NCT01008020	COMPLETED	Influenza Infection	Masahiro Morikawa	2009-11
NCT00516243	COMPLETED	Estrogen Receptor-negative Breast Cancer; Progesterone Receptor-negative Breast Cancer; Stage I Breast Cancer; Stage II Breast Cancer; Stage IIIA Breast Cancer; Stage IIIB Breast Cancer	National Cancer Institute (NCI)	2007-07	PHASE1
NCT01969994	COMPLETED	ADME	The Institutes for Pharmaceutical Discovery, LLC	2009-12
NCT00812448	COMPLETED	Influenza Infection	University of Shizuoka	2008-12
NCT00944827	COMPLETED	Hypercholesterolemia	University of Thessaly	2007-09	PHASE2
NCT00448513	COMPLETED	Healthy	University of Shizuoka	2007-06
NCT00573885	COMPLETED	Lung Cancer; Tobacco Use Disorder	British Columbia Cancer Agency	2008-01	PHASE2
NCT01340599	TERMINATED	Stage I Prostate Cancer; Stage IIA Prostate Cancer; Stage IIB Prostate Cancer	Case Comprehensive Cancer Center	2006-10	PHASE2
NCT00091325	COMPLETED	Unspecified Adult Solid Tumor, Protocol Specific	University of Arizona	2004-10	PHASE1
NCT00611416	COMPLETED	Obesity	University of Copenhagen	2005-11
NCT00239213	COMPLETED	Influenza Infection	University of Shizuoka	2005-11

(data from https://clinicaltrials.gov, updated on 2025-09-05)

Check the (+)-Catechin product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

(+)-Catechin functions as an antioxidant flavonoid that scavenges reactive oxygen species and inhibits pro-inflammatory cascades, thereby mitigating downstream lipid peroxidation and suppressing cell stress pathways. By preserving mitochondrial function and attenuating oxidative damage, (+)-catechin demonstrates anti-proliferative and cytoprotective effects directly applicable to clinical trials in bladder cancer, cirrhosis, and muscular disorders.

Appendix RUO and cGMP Quality Standards

Quality Dimension	RUO (Research Use Only)	cGMP (Current Good Manufacturing Practice)
Clinical Applicability	Prohibited in human clinical trials or medical diagnostics.	Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status	Non-regulated grade; exempt from drug manufacturing laws.	Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment	Unclassified analytical or research laboratories.	Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control	Basic purity and activity testing.	Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation	Basic equipment calibration; no process validation required.	Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance	Vendor self-declared without required formal QMS.	Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact	High risk of IND rejection if used as a critical raw material.	Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).